Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis

Authors: Angela Devine, Rebecca Harvey, Aung Myat Min, Mary Ellen T. Gilder, Moo Koh Paw, Joy Kang, Isabella Watts, Borimas Hanboonkunupakarn, François Nosten, Rose McGready

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Data on the cost effectiveness of hepatitis B virus (HBV) screening and vaccination strategies for prevention of vertical transmission of HBV in resource limited settings is sparse.

Methods

A decision tree model of HBV prevention strategies utilised data from a cohort of 7071 pregnant women on the Thailand-Myanmar border using a provider perspective. All options included universal HBV vaccination for newborns in three strategies: (1) universal vaccination alone; (2) universal vaccination with screening of women during antenatal visits with rapid diagnostic test (RDT) plus HBV immune globulin (HBIG) administration to newborns of HBV surface antigen positive women; and (3) universal vaccination with screening of women during antenatal visits plus HBIG administration to newborns of women testing HBV e antigen positive by confirmatory test. At the time of the study, the HBIG after confirmatory test strategy was used. The costs in United States Dollars (US$), infections averted and incremental cost effectiveness ratios (ICERs) were calculated and sensitivity analyses were conducted. A willingness to pay threshold of US$1200 was used.

Results

The universal HBV vaccination was the least costly option at US$4.33 per woman attending the clinic. The HBIG after (RDT) strategy had an ICER of US$716.78 per infection averted. The HBIG after confirmatory test strategy was not cost-effective due to extended dominance. The one-way sensitivity analysis showed that while the transmission parameters and cost of HBIG had the biggest impact on outcomes, the HBIG after confirmatory test only became a cost-effective option when a low test cost was used or a high HBIG cost was used. The probabilistic sensitivity analysis showed that HBIG after RDT had an 87% likelihood of being cost-effective as compared to vaccination only at a willingness to pay threshold of US$1200.

Conclusions

HBIG following confirmatory test is not a cost-effective strategy for preventing vertical transmission of HBV in the Thailand-Myanmar border population. By switching to HBIG following rapid diagnostic test, perinatal infections will be reduced by nearly one third. This strategy may be applicable to similar settings for marginalized populations where the confirmatory test is not logistically possible.
Appendix
Available only for authorised users
Literature
1.
2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefPubMed
3.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef
4.
5.
6.
Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987;17(1–2):69–79.CrossRefPubMed
7.
Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics. 2013;131(4):e1135–43.CrossRefPubMedPubMedCentral
8.
Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, Weissman JY, Krugman S. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257(19):2612–6.CrossRefPubMed
9.
Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, Gudavalli M, Krugman S. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA. 1985;253(12):1740–5.CrossRef
10.
Zanetti AR, Magliano EM, Tanzi E, Ferroni P, Pirovano G, Pizzocolo G, Pillan N, Zunin C. HBIG immunoprophylaxis of babies born to HBsAg carrier mothers. Dev Biol Stand. 1983;54:383–9.PubMed
11.
Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489–92.PubMed
12.
Wheeley SM, Jackson PT, Boxall EH, Tarlow MJ, Gatrad AR, Anderson J, Bissenden J. Prevention of perinatal transmission of hepatitis B virus (HBV): a comparison of two prophylactic schedules. J Med Virol. 1991;35(3):212–5.CrossRefPubMed
13.
World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016-2021. Geneva: World Health Organization; 2016.
14.
Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(Rr-16):1–31.PubMed
15.
Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8):734–46.CrossRefPubMed
16.
Resti M, Azzari C, Rossi ME, Adami Lami C, Tucci F, Vierucci A. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses. Vaccine. 1991;9(1):15–8.CrossRefPubMed
17.
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329–39.CrossRefPubMed
18.
Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–408.CrossRefPubMed
19.
Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–6.CrossRefPubMed
20.
21.
Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines. 2009;8(7):907–20.CrossRefPubMed
22.
Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Pub Health. 2008;18(3):275–82.CrossRef
23.
Beutels P. Economic evaluations applied to HB vaccination: general observations. Vaccine. 1998;16(Suppl):S84–92.CrossRefPubMed
24.
Lee D, Park SM. Cost-effectiveness analysis of hepatitis B vaccination strategies to prevent perinatal transmission in North Korea: selective vaccination vs. universal vaccination. PLoS One. 2016;11(11):e0165879.
25.
Barbosa C, Smith EA, Hoerger TJ, Fenlon N, Schillie SF, Bradley C, Murphy TV. Cost-effectiveness analysis of the national perinatal hepatitis B prevention program. Pediatrics. 2014;133(2):243–53.CrossRefPubMed
26.
Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123(5):929–37.CrossRefPubMedPubMedCentral
27.
28.
Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S. Hepatitis B control in the World Health Organization's western Pacific region: targets, strategies, status. Vaccine. 2013;31(Suppl 9):J85–92.CrossRefPubMed
29.
Banks T, Kang J, Watts I, Tyrosvoutis ME, Min AM, Tun NW, Keereecharoen L, Simmawong W, Wanyatip S, Hanboonkunupakarn B, et al. High hepatitis B seroprevalence and risk factors for infection in pregnant women on the Thailand-Myanmar border. J Infect Dev Ctries. 2016;10(4):384–8.CrossRefPubMed
30.
Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, Rijken M, Boel M, McGready R, Proux S, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med. 2013;10(3):e1001398.CrossRefPubMedPubMedCentral
31.
McGready R, Boel M, Rijken MJ, Ashley EA, Cho T, Moo O, Paw MK, Pimanpanarak M, Hkirijareon L, Carrara VI, et al. Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986-2010. PLoS One. 2012;7(7):e40244.CrossRefPubMedPubMedCentral
32.
Parr M, Dabu CP, Wai NS, Say PS, Ner M, Tun NW, Min A, Gilder ME, Nosten FH, McGready R. Clinical audit to enhance safe practice of skilled birth attendants for the fetus with nuchal cord: evidence from a refugee and migrant cohort. BMC Pregnancy Childbirth. 2014;14:76.CrossRefPubMedPubMedCentral
33.
White AL, Min TH, Gross MM, Kajeechiwa L, Thwin MM, Hanboonkunupakarn B, Than HH, Zin TW, Rijken MJ, Hoogenboom G, et al. Accelerated training of skilled birth attendants in a marginalized population on the Thai-Myanmar border: a multiple methods program evaluation. PLoS One. 2016;11(10):e0164363.CrossRefPubMedPubMedCentral
34.
White AL, Carrara VI, Paw MK, Malika, Dahbu C, Gross MM, Stuetz W, Nosten FH, Mcgready R. High initiation and long duration of breastfeeding despite absence of early skin-to-skin contact in Karen refugees on the Thai-Myanmar border: a mixed methods study. Int Breastfeed J. 2012;7(1):19.CrossRefPubMedPubMedCentral
35.
R Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017.
36.
37.
StataCorp. Stata Statistical Software: Release 14. College Station: StataCorp LP; 2015.
38.
Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105(2):94–8.CrossRefPubMed
39.
Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. E antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294(14):746–9.CrossRefPubMed
40.
Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–102.CrossRefPubMed
41.
Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, Chen RJ, Margolis HS, Huang CH, Maynard JE. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985;76(5):713–8.PubMed
42.
Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India. J Med Virol. 1987;21(2):137–45.CrossRefPubMed
43.
Ratnam S, Tobin AM. Comparative evaluation of commercial enzyme immunoassay kits for detection of hepatitis B seromarkers. J Clin Microbiol. 1987;25(2):432–3.PubMedPubMedCentral
44.
Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP, Prince A. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang. 2010;98(3 Pt 2):403–14.CrossRefPubMedPubMedCentral
45.
46.
47.
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24.CrossRefPubMed
48.
Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30.CrossRefPubMedPubMedCentral
49.
Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol. 2003;38(2):215–22.CrossRefPubMed
50.
Griffiths UK, Hutton G. Das Dores Pascoal E. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan. 2005;20(1):50–9.CrossRefPubMed
51.
Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252–9.CrossRefPubMed
52.
Guidozzi F, Schoub BD, Johnson S, Song E. Should pregnant urban south African women be screened for hepatitis B? S Afr Med J. 1993;83(2):103–5.PubMed
53.
Brook MG, Lever AM, Kelly D, Rutter D, Trompeter RS, Griffiths P, Thomas HC. Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med. 1989;71(264):313–7.PubMed
54.
Jonsson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J. 1987;63(Suppl 2):27–32.PubMed
55.
Koretz RL. Universal prenatal hepatitis B testing: is it cost-effective? Obstet Gynecol. 1989;74(5):808–14.PubMed
56.
Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181.CrossRefPubMedPubMedCentral
57.
Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011;52(11):1294–306.CrossRefPubMedPubMedCentral
58.
Guinto RL, Curran UZ, Suphanchaimat R, Pocock NS. Universal health coverage in 'One ASEAN': are migrants included? Glob Health Action. 2015;8:25749.CrossRef
59.
Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol. 2009;50(4):805–16.CrossRefPubMed
60.
Bulbul A, Karadag A, Koklu E, Pamuk U, Sarici SU. Anaphylactic shock due to hepatitis B immunoglobulin in a newborn. J Matern Fetal Neonatal Med. 2010;23(10):1257–9.CrossRefPubMed
61.
Khuroo MS, Khuroo NS, Khuroo MS. Accuracy of rapid point-of-care diagnostic tests for hepatitis B surface antigen-a systematic review and meta-analysis. J Clin Exp Hepatol. 2014;4(3):226–40.CrossRefPubMedPubMedCentral
62.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefPubMed
63.
64.
Kaji A, Parker DM, Chu CS, Thayatkawin W, Suelaor J, Charatrueangrongkun R, Salathibuppha K, Nosten FH, McGready R. Immunization coverage in migrant school children along the Thailand-Myanmar border. J Immigr Minor Health. 2016;18(5):1038–45.CrossRefPubMed
65.
Thio CL, Guo N, Xie C, Nelson KE, Ehrhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis. 2015;15(8):981–5.CrossRefPubMed
66.
Torreele E, Mazzucato M. Fair vaccine pricing please, not random acts of charity. BMJ. 2016;355:i6173.CrossRefPubMed
Metadata
Title
Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis
Authors
Angela Devine
Rebecca Harvey
Aung Myat Min
Mary Ellen T. Gilder
Moo Koh Paw
Joy Kang
Isabella Watts
Borimas Hanboonkunupakarn
François Nosten
Rose McGready
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2660-x

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue

Research article

Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany

Research article

Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis

Research article

Glycosaminoglycans are involved in bacterial adherence to lung cells

Research article

Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data

Research article

Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway

Study protocol

Disease burden and antimicrobial resistance of invasive group B streptococcus among infants in China: a protocol for a national prospective observational study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits